M. Polee

A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study.

W. M. Smit, H. Hollema, F. Erdkamp, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients

Anne M Johnson, A. Trkola, J. Sterne, 2007, Journal of acquired immune deficiency syndromes.

A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study.

W. M. Smit, H. Hollema, P. Willemse, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of the combination cisplatin, etoposide, 5-fluorouracil and folinic acid in patients with advanced squamous cell carcinoma of the esophagus

A. van der Gaast, G. Stoter, P. Siersema, 2001, Anti-cancer drugs.

Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy

W. Hop, M. Polée, A. van der Gaast, 2003, British Journal of Cancer.

Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer

J. Verweij, M. Polée, A. van der Gaast, 2002, British Journal of Cancer.